scholarly journals The Effects of Long-Term Administration of Sodium Nedocromil on Bronchial Hypereactivity

2003 ◽  
Vol 1 (3) ◽  
pp. 119-123 ◽  
Author(s):  
G. Ilonidis ◽  
G. Anogianakis ◽  
CH. Trakatelli ◽  
A. Anogeianaki ◽  
M. Chomatidis ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Term Treatment ◽  
Bronchial Hyperreactivity ◽  
Methacholine Challenge ◽  
Intrinsic Asthma ◽  
Group I ◽  
Long Term Treatment ◽  
The Mean ◽  
Group Ii

The effect of long-term treatment with sodium nedocromil on airway hypereactivity was investigated in two groups of 20 patients each. Group I patients presented with allergic asthma while Group II patients presented with intrinsic asthma. For each subject of the two groups, the base FEV1 was measured and nebulized methacholine was administrated in consecutively higher concentrations until a decrease in FEV1 of >20 % was observed. Following measurement, all patients included in the study were treated with 12 mg of sodium nedocromil per day for 12 months. At the end of the treatment, bronchial hyperreactivity was evaluated for a second time by administering the same dosage of methacholine that originally produced a decline in FEV1 of >20 %. In Group I patients (allergic asthma) mean FEV1 was 3126 ml, before challenge, while after methacholine challenge FEV1 was 2400ml. Following 1-year of sodium nedocromil administration the FEV1 was 2601ml (P<0.05). Before treatment, the mean fall in FEV1, following methacholine challenge, was 23.67% while following a 1-year-long sodium nedocromil administration this value reduced to 15.70% (P<0.05). Correspondingly, PC20 was 5.59 while after sodium nedocromil administration it increased to 11.66 (P<0.05). In Group II patients (intrinsic asthma) mean FEV1 was 2750 ml, before challenge, while after methacholine challenge FEV1 was 2066ml. Following 1-year of sodium nedocromil administration the FEV1 was 2223ml (P<0.05). Before treatment, the mean fall in FEV1, following methacholine challenge, was 27.65 % while following a 1-year-long sodium nedocromil administration this value reduced to 21.92 % (P<0.05). Correspondingly, PC20 was 5.91 while after sodium nedocromil administration it increased to 6.19 (P<0.05). The results suggest a positive effect of long-term sodium nedocromil administration in bronchial hyperreactivity for both groups of patients.

The Effects of Long-Term Treatment by Immunotherapy and Fluticazone on Broncial Hyperreactivity

2003 ◽  
Vol 1 (1) ◽  
pp. 13-16
Author(s):  
G. Ilonidis ◽  
G. Anogianakis ◽  
Chr. Trakatelli ◽  
A. Anogeianaki ◽  
J. Giavazis ◽  
...  
Keyword(s):  
Provocation Test ◽  
Term Treatment ◽  
Provocation Tests ◽  
Group I ◽  
Long Term Treatment ◽  
Group Ii ◽  
Male Subjects

Thirty subjects (20 female and 10 male), all allergic to the mites D. Pteronyssinus and D. Farinae, participated in the present study which covered a period of four years. The subjects were randomly divided in two groups. Group I included 10 female and 5 male subjects, with an average age of 25.8 (+/− 3.5) years who received immunotherapy only. Group II had an average age of 31.5 (+/− 4) years and they received immunotherapy along with fluticazone propionate (1000mcg/day). The protocol for immunotherapy was the same for both groups. The basis FEV1 was determined for each subject of both Groups I and II and afterwards they were subjected to provocation tests of nebulized methacholine solution administered in consecutively larger concentrations until a drop in FEV1 >20 % (PC20), was observed. Three years later, when their therapy was completed, all subjects were subjected to the same provocation test and a significant reduction in bronchial hyperactivity was documented for both groups. In particular, for Group I, the percentage of change in FEV1 values was 27.25 +/- 5.23 % and PC20 5.11 +/− 2.64 mg/ml before immunotherapy, while after immunotherapy the same indicators were 22.22 +/- 7.08 % (P<0.05) and 6.85 +/− 4.03 mg/ml, (P<0.05) respectively. For Group II, the percentage of change in FEV1 values was 26.28 +/− 2.5 % and PC20 5.42 +/− 2.5 mg/ml before immunotherapy, while after immunotherapy the same indicators were 12.27 +/- 2.49 % (P<0.01)and 11.64 +/− 5.14 mg/ml, P<0.01 respectively. It is concluded that although significant reduction in hyperreactivity can be achieved through immunotherapy, the combination of immunotherapy with daily fluticazone propionate administration shows the most promising results.

scholarly journals Clinical relevance of a degree of extracapsular extension in a sentinel lymph node in breast cancer patients: a single-centre study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tomasz Nowikiewicz ◽  
Andrzej Kurylcio ◽  
Iwona Głowacka-Mrotek ◽  
Maria Szymankiewicz ◽  
Magdalena Nowikiewicz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Term Treatment ◽  
Extracapsular Extension ◽  
Group Iii ◽  
Metastatic Lesions ◽  
Cancer Metastases ◽  
Group I ◽  
Long Term Treatment

AbstractIn some breast cancer (BC) patients, an examination of lymph nodes dissected during sentinel lymph node biopsy (SLNB) demonstrates a presence of metastatic lesions and extracapsular extension (ECE) in a SLN. This study aimed to evaluate clinical relevance of ECE in BC patients. This is a retrospective analysis of 891 patients with cancer metastases to SLN, referred to supplementary axillary lymph node dissection (ALND), hospitalized between Jan 2007 and Dec 2017. Clinical and epidemiological data was evaluated. Long-term treatment outcomes were analysed. In 433 (48.6%) patients, cancer metastases were limited to the SLN (group I), in 61 (6.8%) patients the SLN capsule was exceeded focally (≤ 1 mm—group II). In 397 (44.6%) patients, a more extensive ECE was found (> 1 mm—group III). Metastases to non-sentinel lymph nodes (nSLNs) were diagnosed in 27.0% patients from group I, 44.3% patients from group II and in 49.6% patients from group III. No statistically significant differences were observed in long-term treatment outcomes for compared groups. The presence of ECE is accompanied by a higher stage of metastatic lesions in the lymphatic system. The differences in this respect were statistically significant, when compared to the group of ECE(−) patients. ECE, regardless of its extent, did not impact the long-term treatment results. ECE remains an indication for supplementary ALND and for other equivalent cancer treatment procedures, regardless of ECE size.

Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 306-306
Author(s):  
Y. Kang ◽  
C. Yoo ◽  
B. Ryoo ◽  
H. Chang ◽  
J. Lee ◽  
...  
Keyword(s):  
Plasma Level ◽  
Gastrointestinal Stromal Tumors ◽  
Plasma Concentrations ◽  
Term Treatment ◽  
Albumin Concentration ◽  
Stromal Tumors ◽  
Long Term Treatment ◽  
The Mean ◽  
Median Interval

306 Background: Pharmacokinetic study in patients with gastrointestinal stromal tumors (GISTs) suggested that plasma concentrations of imatinib decrease following long-term exposure. We therefore measured changes in imatinib plasma trough levels (Cmin) after long-term exposure. Methods: Between November 2009 and May 2010, follow-up (FU) imatinib Cmin was measured in 65 patients who received the same dose of imatinib for at least 9 months after a previous baseline (BL) measurement. Total 244 blood samples were obtained (127 at BL and 117 at FU) and plasma level was measured by liquid chromatography-tandem mass spectrometry. Results: Median patient age was 54 years (range, 28–76 years) and 42 (64.6%) patients were male. Sixty-one (93.8%) patients were treated with 400 mg/day imatinib and 4 (6.2%) with 300 mg/day. The median interval from initiation of imatinib to BL test was 6.4 months (range, 0.5–66.6 months), and the median interval between BL and FU test was 13.1 months (range, 9.6–18.4 months). The mean ± standard deviation imatinib Cmin was significantly higher at FU than at BL (1442 ± 693 ng/mL vs 1221 ± 624 ng/mL, p<0.001). The mean inter- and intra-subject variabilities were 49.2% and 25.5%, respectively, at BL, and 44.2% and 20.4%, respectively, at FU. Multivariate analysis showed a significant correlation between the ratio of FU to BL imatinib Cmin and that of albumin (r=-0.397, p=0.001). In per-sample analysis, imatinib Cmin was significantly correlated with age, hemoglobin, albumin, creatinine clearance, previous major gastrectomy and time between initiation of imatinib and plasma level tests. Conclusions: Steady-state imatinib Cmin did not decrease but remained stable in most GIST patients during long-term treatment. Changes in imatinib Cmin were associated with changes in albumin concentration. Monitoring of imatinib Cmin only for concerns about time-dependent decreases in imatinib exposure is not necessary. [Table: see text]

Effects of methylthiouracil treatment on the growth and moult of cashmere fibre in goats

1996 ◽  
Vol 62 (3) ◽  
pp. 513-520 ◽  
Author(s):  
S. M. Rhind ◽  
S. R. McMillen
Keyword(s):  
Fibre Diameter ◽  
Live Weight ◽  
Term Treatment ◽  
Hair Follicles ◽  
Long Term Treatment ◽  
Fibre Growth ◽  
The Mean ◽  
Secondary Fibre

AbstractThe effect of long-term treatment of goats with methylthiouracil on the timing, amount and quality of secondary fibre (cashmere) growth and timing of cashmere moult in goats was investigated. From early June, groups of 10 Icelandic × Scottish feral goats were dosed orally each day, for a 15-month period, with 5 mg methylthiouracil per kg live weight in 30 ml water (treated; T) or with water only (control; C). Treatment with methylthiouracil resulted in a significant reduction (P < 0·05) in the proportion of active secondary hair follicles present during March. This was associated with a delayed onset of moult of cashmere in T compared with C goats at both the head (11 March v. 23 February; s.e. 3·33 days; P< 0·05) and mid side (27 March v. 26 February; s.e. 3·58 days; P < 0·001). There was no effect on the time of onset (C, 19 July; T, 19 July; s.e. 5·84 days) or cessation of cashmere fibre growth (C, 9 December; T, 8 December; s.e. 1·69 days) or the mean growth rate (C, 0·473 mm/day; T, 0·451 mm/day; s.e. 0·025) and fibre diameter (C, 16·9 μm; T, 15·4 jim; s.e. 0·266). Wlien present in the fleece, the mean weight and proportion of cashmere was higher in C than in T goats (P < 0·05). It is concluded that methylthiouracil treatment altered secondary follicle activity and the time of onset of the moult of cashmere and that these changes may be a result of reduced triiodothyronine production from thyroxine and associated secondary changes in profiles of insulin and IGF-1.

Dissociation of symptom scores and bronchial hyperreactivity: Study in asthmatic children on long-term treatment with inhaled beclomethasone dipropionate

1992 ◽  
Vol 13 (2) ◽  
pp. 71-77 ◽  
Author(s):  
Marie R. Benoist ◽  
Jean J. Brouard ◽  
Patrick Rufin ◽  
Serge Waernessyckle ◽  
Jacques de Blic ◽  
...  
Keyword(s):  
Beclomethasone Dipropionate ◽  
Term Treatment ◽  
Bronchial Hyperreactivity ◽  
Asthmatic Children ◽  
Long Term Treatment ◽  
Symptom Scores

scholarly journals Short and Long-Term Follow up Results of Daily 5 Mg Tadalafil as a Treatment for Erectile Dysfunction and Premature Ejaculation

2021 ◽  
Author(s):  
Tarek Gharib ◽  
Ibrahim Abdelal ◽  
Adel Elatreisy ◽  
Elsayed Salih ◽  
Ahmed Sebaey
Keyword(s):  
Erectile Dysfunction ◽  
Premature Ejaculation ◽  
P Value ◽  
Group I ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
The Mean ◽  
Group Ii

Abstract Objective: To evaluate effectiveness and safety of a 5mg tadalafil daily treatment for men with erectile dysfunction (ED) and premature ejaculation (PE) and assessment of long-term follow up by persistence of improvement 2 years after stoppage of tadalafil.Materials and Methods: The study included 160 patients diagnosed with erectile dysfunction from April 2018 to June 2020. All were evaluated using the international index of erectile function questionnaire-5 (IIEF-5) to evaluate ED and intravaginal ejaculatory latency time (IELT) for PE. Patients subdivided into two equal groups. I included 80 patients treated with tadalafil 5 mg daily for 3 months, and group II included 80 patients treated with a placebo for same period. After 3 months treatment and 2 years later after stoppage of tadalafil, all patients were assessed for ED and PE using the same questionnaires. Results: The mean IELT and IIEF pretreatment were 37±11.24 s and 13.2±4.2 respectively for group I, while in group II was 35.98±10.8 s and 13.12±4.11, respectively. After 3 months of treatment, the mean value of IELT in group I showed a highly significant improvement from 37±11.24 sec to 120.5±47.37 sec (p-value < 0.001), but for group II, the mean values of IELT showed no significant improvement from baseline 35.98±10.8 to endpoint 39.43±13.6 ( p-value > 0.05). As regarding the IIEF, there was a highly significant improvement from baseline 13.2±4.2 to endpoint 20.45±4.5 in group I (p-value < 0.001) while there was no significant difference in group II from baseline 13.12±4.11 to endpoint 15±4.84 (p-value > 0.05) . 2 years later after stoppage of tadalafil , 75 patients from group I complete follow up and there was significant improvement in IELT and IIEF form base line (37±11.24) (13.2±4.2) to endpoint (98±18.3) (19.1±2.3) respectively but less than the results after 3 months treatment.ConclusionDaily Tadalafil 5 mg was effective, tolerable, and safe treatment for patients suffering from ED and PE. Long-term follow up after 2 years declared persistence of significant improvement.

BIOCHEMICAL, VIROLOGICAL AND THE FIBROSIS RESPONSES TO TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBV-RELATED COMPENSATED CIRRHOSIS

2016 ◽  
pp. 14-18
Author(s):  
Van Huy Tran ◽  
Phuoc Bao Quan Nguyen
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Acoustic Radiation ◽  
Term Treatment ◽  
Remarkable Improvement ◽  
Compensated Cirrhosis ◽  
Long Term Treatment ◽  
Tenofovir Df ◽  
Cirrhotic Patients ◽  
The Mean

Background: Preliminary studies showed anti HBV nucleoside analogues treatment might improve the histopathology and improve the survival of the cirrhotic patients. Data about efficacy of anti-HBV treatment in Vietnamese cirrhotic patients was still very limited. This study was aimed at assessing the biochemical, virological and the fibrosis responses to Tenofovir disoproxil fumarate (Tenofovir DF) in patients with HBVrelated compensated cirrhosis. Patients and methods: 48 patients of HBV-related compensated cirrhosis, diagnosed by Acoustic radiation Forced Imaging (ARFI), were enrolled. Tenofovir DF was given at dose of 300 mg per day, followed in 24 months. Results: ALT normalization and HBV DNA responses were found in 91.7% and 87.5%, respectively, of all patients. The mean of SWV was significantly improved after 24 months, from 2.16 ± 0.28 m/s down to 1.80± 0.22 m/s after 24 months of tenofovir treatment. Especially, 15 patients (31.2%) have obtained a remarkable improvement of fibrosis from F4 down to F3 or even F2. Conclusion: Tenofovir treatment in patients with HBV- related compensated cirrhosis may provide not only biochemical and virological responses but also improves in liver fibrosis, especially after long-term treatment. Key words: HBV, Tenofovir disoproxil fumarate, compensated cirrhosis, ARFI

Sign in / Sign up

Export Citation Format

Share Document